Holdings in Company
02 September, 2010
Total Voting Rights
31 August, 2010
Issue of Equity
03 August, 2010
NOMAD Change of Name
12 July, 2010
Sareum to Present at EPIC 2010
23 June, 2010
Sareum to Present at BIO 2010
05 May, 2010
Scientific Advisory Board Appointment
26 April, 2010
Collaboration Agreement
16 March, 2010
Half Yearly Report
16 February, 2010
The ICR, Sareum and CRT
20 January, 2010
Result of AGM
16 December, 2009
Issue of Options
04 December, 2009
Holdings in Company
24 November, 2009
Availability of Report & Accounts
20 November, 2009
Sareum to Present at BIO-Europe 2009
02 November, 2009
Total Voting Rights
30 October, 2009
Final Results
27 October, 2009
Holding(s) in Company
19 October, 2009
NOMAD - Change of Name
19 October, 2009
Holding(s) in Company
15 October, 2009
Issue of Equity
12 October, 2009
Issue of Equity
12 October, 2009
Holding(s) in Company
09 October, 2009
Cancer Research Programme to be Presented
06 October, 2009
Total Voting Rights
30 September, 2009
Holding(s) in Company
21 September, 2009
Holding(s) in Company
16 September, 2009
Holding(s) in Company
10 September, 2009
Issue of Equity
08 September, 2009
Previous releases
2010 2009 2008 2007 2006 2005 2004
News feed
requires RSS news reader
|
(AIM: SAR) |
24 November 2009 |
SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Holdings in Company
The Company has been notified today that, following a sale of shares, Mr and Mrs Leonard Licht hold 56,700,000 ordinary shares in the capital of the Company, equivalent to 4.82 per cent. of the issued share capital of the Company.
Enquires:
|
Sareum Holdings plc |
|
|
Tim Mitchell |
01223 497 700 |
|
|
|
|
Merchant John East Securities Limited (Nominated Adviser) |
|
|
Simon Clements/Bidhi Bhoma |
020 7628 2200 |
|
|
|
|
Hybridan LLP (Broker) |
|
|
Claire Noyce/Stephen Austin |
020 3159 5085 |
Notes for editors:
About Sareum Holdings plc
Sareum is a drug discovery company, headquartered in Cambridge UK, that is focused on producing targeted small molecule therapeutics to address unmet medical needs, primarily in cancer.
Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.
Sareum Holdings plc joined the AIM market of the London Stock Exchange in October 2004, trading under the symbol SAR. For further information, please visit www.sareum.co.uk
Requires MS Word
Requires Adobe Acrobat Reader